Solentim agrees exclusive distribution deal with Matrixome to supply clinical manufacturing grade laminin to cell therapy market
Bournemouth, UK, 10th June 2021 / Sciad Newswire / Solentim, the trusted global leader for solutions to create, isolate, and characterize the highest value cells for the development of new biological medicines, has today announced an exclusive distribution agreement with Matrixome Inc. (Japan) for use in conjunction with Solentim’s instrumentation. Under the new agreement, Solentim will add a clinical manufacturing-grade laminin matrix as part of its offering for stem cell therapy customers.
Dr Mark Truesdale, CEO Solentim, said, “The supply of the clinical manufacturing grade laminin in conjunction with the VIPS, our industry-leading single cell seeder, will now enable our cell therapy customers to confidently establish their workflow in process development using MatriClone, knowing that they can subsequently replicate this with the clinical-grade laminin for transfer to GMP manufacturing.”
Making clonally-derived GMP Master Cell Banks will continue to be a key workflow for many allogeneic cell therapy companies. Access to the clinical-grade laminin builds on the existing availability of MatriClone matrix which Solentim has been selling to its instrument customers for research-use-only purposes. Significantly, the combination of using the soluble form of the laminin matrix in combination with the VIPS single cell cloning instrument has also recently been approved for a US patent application.
For further information, please contact:
Global Marketing Manager
T: +44 (0)1202 798510
Solentim Media Relations – Sciad Communications
T: +44 (0)20 3405 7892
Notes to editors
Solentim is the trusted global leader in workflows for antibody and cell-based therapies. Our assurance rich technologies enable the isolation, growth and characterization of high value cells while our data driven platform enables smarter decision earlier in the process. Together, our customers experience faster workflows, confidently designed for regulatory environments.
Matrixome Inc. is a venture company out of Osaka University’s Institute for Protein Research providing a unique laminin technology. Already a gold standard in Japan for clinical and research use, Matrixome’s E8 fragment technology, pioneered by Professor Sekiguchi after 20 years of research, provides numerous advantages over other ECM substrates and has already been used in countless peer-reviewed papers, clinical stem cell banks, and clinical trials.